• In late July 2026, Teladoc Health reported second‑quarter results showing sales declining to US$606.93 million and a wider net loss of US$38.91 million, alongside lower basic loss per share from continuing operations of US$0.21.
• Management also issued guidance calling for continued losses in the third quarter and full year 2026, highlighting ongoing pressure from the BetterHelp mental health unit as more users move toward insurance-covered care.
• We’ll now examine how Teladoc’s weaker BetterHelp performance and lowered full‑year revenue guidance could reshape the company’s broader investment narrative.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Teladoc Health Investment Narrative Recap

To own Teladoc today, you need to believe virtual and hybrid care can scale into a larger, more efficient business even while it remains unprofitable. The key near term catalyst is whether Teladoc can stabilise BetterHelp by shifting users to insurance-covered care. The latest results and softer guidance directly pressure that catalyst and underline the largest risk right now: ongoing revenue declines and margin strain as the model transitions away from cash pay.

The most relevant new information is Teladoc’s updated 2026 guidance, which now calls for full year revenue of US$2,362 million to US$2,447 million and a net loss of US$181 million to US$136 million. This reset ties closely to BetterHelp’s weaker cash pay trends and confirms that the insurance pivot is already affecting headline numbers. For investors watching catalysts, it raises the importance of tracking whether future quarters show any stabilisation in BetterHelp volumes and margins.

Yet behind Teladoc’s insurance pivot, investors should be aware that...

Teladoc Health's narrative projects $2.6 billion revenue and $172.9 million earnings by 2029. This requires essentially flat yearly revenue growth and about a $344 million earnings increase from -$171.1 million today.

Uncover how Teladoc Health's forecasts yield a $7.97 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were assuming Teladoc could reach about US$2.7 billion in revenue and roughly US$63 million in earnings, but the latest BetterHelp-driven shortfall may challenge those expectations and shows how differently you and other investors might view the same risks and opportunities.

Explore 3 other fair value estimates on Teladoc Health - why the stock might be worth just $7.97!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 55 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 57 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.